We create treatments that go beyond rare disease
to solve the world's most complex healthcare challenges
Press Releases
- MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIBView PDF
- JCR Pharmaceuticals Joins “Relay For Life of Ashiya” in Support of the Cancer CommunityView PDF
- Support for People and Communities Affected by the 2026 Kumamoto Prefecture EarthquakeView PDF
- FY2026 First Quarter Results Briefing Session - Script
News
- Notice of Resolutions Passed at The 51st Ordinary General Meeting of Shareholders
- Shareholders and Investors Please click here for details regarding the convocation of The 51st Ordinary General Meeting of Shareholders.
- Other Matters Subject to Measures for Electronic Provision When Convening the 51st Ordinary General Meeting of Shareholders
- Notice of Convocation of The 51st Ordinary General Meeting of Shareholders
As a Global Specialty Pharma
in the Rare Disease Field
We are one of the few biopharmaceutical companies in Japan
that drive the entire value chain-from research and development to manufacturing and commercialization.
With strong R&D and manufacturing capabilities, we have continued to push the limits of possibility.
Rare diseases present ongoing challenges, yet we remain committed to bringing hope to more patients.
At JCR, we will keep turning new treatment possibilities into reality.
01Our Commitment to Rare Diseases
02Advancing with Unique Biotechnologies and Expertise
03A Relentless Pursuit of Manufacturing Excellence
ResearchandDevelopment
At JCR Pharma, we leverage our proprietary biotechnology and accumulated expertise to develop high‑value, innovative therapies.
By delivering new treatment options, we aim to contribute to better health and the future of medicine.
